Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis.
Veeck J; Niederacher D; An H; Klopocki E; Wiesmann F; Betz B; Galm O; Camara O; Dürst M; Kristiansen G; Huszka C; Knüchel R; Dahl E; Oncogene, 2006, vol. 25, issue 24, p 3479, ISSN 09509232. ISBN 09509232.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via CrossRef